Investor Presentaiton

Sartorius Group Cell and gene therapies (CGT) an increasingly relevant market segment ~30% of biopharma pipeline is focusing on CGT1 ~70% Other biologics -30% CGT Number of commercial processes is expanding rapidly ~60 approved CGT globally¹ 11 CGT approvals in 2022 and 2023 alone >6,000 CGT candidates in development¹ ■ 7 new CGT (2022: 5) approvals in 2023 out of 42 BLA approvals in total (2022: 31) 2 10-20 CGT approvals expected p.a. by 20252 1 GlobalData, October 2023 2 FDA, includes CDER and CBER approvals 12 SARTORIUS

View entire presentation